
Opinion|Videos|November 13, 2025
FDA Approvals, Patient Selection, and SC Amivantamab
Panelists discuss how recent FDA approvals and SC amivantamab data support broader use of subcutaneous therapy in NSCLC.
Advertisement
Episodes in this series

Panelists discuss how recent FDA approvals for subcutaneous (SC) oncology agents are expanding therapeutic flexibility. They highlight approvals for SC versions of atezolizumab, nivolumab, and pembrolizumab, as well as clinical data from the PALOMA trials evaluating SC amivantamab. The discussion reviews findings demonstrating equivalent efficacy, safety, and pharmacokinetics to intravenous (IV) formulations. Panelists also address patient selection criteria, clinical considerations for integrating SC therapies with IV regimens, and how these innovations enhance workflow efficiency and patient experience.
Advertisement
Related to this article

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.

The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR antibody-positive gMG.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial
3
Menopause Benefit Design Should Prioritize Access, Total Cost of Care
4
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
5

